Please assess the completion status of the following clinical trial:

Trial Title: A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females between 18 and 55 years (inclusive) of age.~* Non-smoking (by declaration) for a period of at least 6 months.~* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.~* Haematology and Chemistry values within normal ranges or with no clinical significance~* Subjects who provide written informed consent to participate in the study~Exclusion Criteria:~* Known history of significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications.~* Ongoing flu symptoms or influenza~* Any clinically significant abnormality upon physical examination or in the clinical laboratory test at screening visit.~* Treatment with immune immunosuppressant drugs or other immune enhancing drugs.~* Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within one year prior to the screening visit.~* Administration of any vaccine 30 days before the screening visit.~* Known history of drug or alcohol abuse.~* Known history of HIV, hepatitis C or B virus (HCV or HBV)~* Subjects with known Guillain Barré Syndrome in the past~* 2 or more hospitalization within the last year prior to screening visit~* Increased liver enzymes 2.5 times above the upper reference level~* Known hypersensitivity and/or allergy to any drugs~* Any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator.~* Subjects who participated in another clinical study within 30 days prior to study entry~* Subjects who are non-cooperative or unwilling to sign consent form.~* Pregnant or lactating women at entry to study and those that are unwilling to agree to continue precautions for two months after completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Multimeric-001 250 Mcg (Type: EXPERIMENTAL): Multimeric-001 250 Mcg in PBS
- Adjuvanted Multimeric-001 250 Mcg (Type: EXPERIMENTAL): 250 Mcg in montanide
- Phosphate Buffered saline (Type: PLACEBO_COMPARATOR): Non-adjuvanted placebo
- Adjuvanted PBS (Type: PLACEBO_COMPARATOR): Adjuvant was montanide
- Multimeric-001 500 Mcg (Type: EXPERIMENTAL): Multimeric-001 in PBS
- Adjuvanted Multimeric-001 500 Mcg (Type: EXPERIMENTAL): Adjuvant was montanide
- Multimeric-001 125 Mcg (Type: EXPERIMENTAL): Multimeric-001 in PBS

Based on this trial design, predict the completion outcome and termination type (if applicable).